Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805
Actuarial Approach01:20

Actuarial Approach

339
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
339
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

663
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
663
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should We Call Every Cancer a Rare Cancer?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.

Journal of comparative effectiveness research·2026
Same author

Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy.

NPJ precision oncology·2026
Same author

The Cigarette.

JAMA oncology·2025
Same author

Another Feather In The Cap for Posttransplant Cyclophosphamide GVHD Prophylaxis?

JAMA oncology·2025
Same author

Mitigating the Impact of Drug Shortages in Oncology: Lessons Learned From the 2023 Shortages of Carboplatin and Cisplatin.

Cancer journal (Sudbury, Mass.)·2025
Same journal

The Promise of Direct-Acting Antiviral Therapies to Improve Care and Outcomes in Patients With Cancer Who Have Chronic Hepatitis C Infection.

Journal of oncology practice·2019
Same journal

Oncologic Implications of Chronic Hepatitis C Virus Infection.

Journal of oncology practice·2019
Same journal

Considerations for Long-Term Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and Cancer.

Journal of oncology practice·2019
Same journal

Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists.

Journal of oncology practice·2019
Same journal

Nationwide Survey of Patients' Perspectives Regarding Their Radiation and Multidisciplinary Cancer Treatment Experiences.

Journal of oncology practice·2019
Same journal

Management of Brain Metastases in Non-Small-Cell Lung Cancer.

Journal of oncology practice·2019
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

2.0K

Value-Based Calculators in Cancer: Current State and Challenges.

Chadi Nabhan1, Bruce A Feinberg1

  • 1Cardinal Health, Dublin, OH.

Journal of Oncology Practice
|June 16, 2017
PubMed
Summary
This summary is machine-generated.

Value calculators for cancer care spending offer initial cost-value insights but lack patient perspective. Refinements are needed to fully capture the cancer journey and global costs for better healthcare economics.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

956

Related Experiment Videos

Last Updated: Feb 28, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

2.0K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

956

Area of Science:

  • Health economics
  • Oncology
  • Value-based healthcare

Background:

  • Rising cancer care costs necessitate value assessment tools.
  • Existing methodologies include ASCO Value Framework, NCCN Evidence Blocks, DrugAbacus, and ICER calculator.

Purpose of the Study:

  • To review the advantages and limitations of current cancer care value calculators.
  • To identify opportunities for refining these tools to better incorporate patient perspectives and global costs.

Main Methods:

  • Literature review and critical analysis of prominent value-based methodologies in oncology.
  • Comparative assessment of the ASCO Value Framework, NCCN Evidence Blocks, DrugAbacus, and ICER calculator.

Main Results:

  • Value calculators provide a starting point for cost-value discussions but do not fully integrate the patient journey.
  • Key limitations include insufficient consideration of patient-reported outcomes and the total cost of care across the cancer continuum.

Conclusions:

  • Current value calculators have limitations in reflecting the true value of cancer care from a patient-centric and comprehensive cost perspective.
  • Refinement of these tools is crucial for accurate cost-effectiveness evaluations and informed decision-making by oncologists, payers, and manufacturers.